Affordable Access

Access to the full text

Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease

Authors
  • Arend, Rebecca C.1
  • Jackson-Fisher, Amy2
  • Jacobs, Ira A.2
  • Chou, Jeffrey2
  • Monk, Bradley J.3
  • 1 University of Alabama at Birmingham, USA
  • 2 Pfizer, USA
  • 3 Research Gynecology Program, USA
Type
Published Article
Journal
Cancer Biology & Therapy
Publisher
Landes Bioscience
Publication Date
Jan 11, 2021
Volume
22
Issue
2
Pages
89–105
Identifiers
DOI: 10.1080/15384047.2020.1868937
PMID: 33427569
PMCID: PMC7928025
Source
PubMed Central
Keywords
License
Green

Abstract

Recently approved therapies have contributed to a significant progress in the management of ovarian cancer; yet, more options are needed to further improve outcomes in patients with advanced disease. Here we review the rationale and ongoing clinical trials of novel combination strategies involving chemotherapy, poly ADP ribose polymerase, programmed death 1 (PD-1)/PD-ligand 1 immune checkpoint and/or vascular endothelial growth factor receptor inhibitors. Further, we discuss novel agents aimed at targets associated with ovarian cancer growth or progression that are emerging as potential new treatment approaches. Among them, agents targeted to folate receptor α, tissue factor, and protein kinase-mediated pathways (WEE1 kinase, phosphatidylinositol-3 kinase α, cell cycle checkpoint kinase 1/2, ATR kinase) are currently in clinical development as mono- or combination therapies. If successful, findings from these extensive development efforts may further transform treatment of patients with advanced ovarian cancer.

Report this publication

Statistics

Seen <100 times